Cargando…
Critical reappraisal of remdesivir investigational trials in COVID-19
During disease outbreaks, the pharmaceutical industry generally puts a lot of effort into promoting clinical trials studying their new drugs. We review evidence of the ten most recent reports on remdesivir. We conclude that it is far too premature to identify remdesivir as a curative or life-saving...
Autores principales: | Brouqui, P., Giraud-Gatineau, A., Raoult, D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7567956/ https://www.ncbi.nlm.nih.gov/pubmed/33088576 http://dx.doi.org/10.1016/j.nmni.2020.100745 |
Ejemplares similares
-
WITHDRAWN: Remdesivir investigational trials in coronavirus disease 2019: a critical reappraisal()()
por: Brouqui, P., et al.
Publicado: (2020) -
A Mini Review on Discovery and Synthesis of Remdesivir as an Effective and Promising Drug against COVID-19
por: Zarenezhad, E., et al.
Publicado: (2021) -
Wide Complex Tachycardia Differentiation: A Reappraisal of the State‐of‐the‐Art
por: Kashou, Anthony H., et al.
Publicado: (2020) -
What could explain the late emergence of COVID-19 in Africa?
por: Lalaoui, R., et al.
Publicado: (2020) -
Can hydroxychloroquine be protective against COVID-19-associated thrombotic events ?
por: Devaux, Christian A., et al.
Publicado: (2021)